Alaunos Therapeutics, Inc SEC Filings

Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral, non-hormonal small-molecule candidate for obesity and related metabolic disorders, based on two non-GLP diet-induced obesity mouse studies. Across these models, ALN1003 was associated with weight loss, favorable shifts in body composition, improved insulin-resistance biomarkers, adipose endocrine changes, and markers of improved liver health, including lower liver weight and enzymes and reduced steatosis scores in limited pathology samples.

The company emphasizes that all findings are from non-GLP animal studies, with important limitations and no established human safety or efficacy. Alaunos plans additional preclinical, pharmacology, formulation, and CMC work, as well as a computational chemistry program for next-generation compounds. As of March 31, 2026, it held about $0.354 million in cash and cash equivalents, with a cash runway extending into the second quarter of 2026, and intends to seek additional financing to continue operations and advance its obesity and metabolic disorders program.

Alaunos Therapeutics reported updated preclinical data for ALN1003, its investigational oral metabolic therapy for obesity and related metabolic disorders, from non-GLP diet-induced obesity mouse studies. ALN1003 was associated with significantly lower fasting insulin and HOMA-IR, along with higher adiponectin and an improved adiponectin-to-leptin ratio, suggesting a favorable insulin-resistance-related biomarker profile in these models.

Blinded liver histology in small pathology sets showed qualitative findings consistent with lower hepatic steatosis and lower mean NAS scores in ALN1003-treated animals versus controls. These results remain early, non-GLP, and preclinical, and ALN1003 has not been tested in humans. Alaunos also disclosed cash and cash equivalents of about $0.354 million as of March 31, 2026, with a cash runway extending into the second quarter of 2026 and plans to seek additional financing.

Alaunos Therapeutics, Inc. reported a Q1 2026 net loss of $1.0 million with no product revenue and total assets of $1.9 million. Cash and cash equivalents were just $0.35 million, and management expects this to fund operations only into the second quarter of 2026.

Stockholders’ equity was $1.29 million, below Nasdaq’s $2.5 million minimum equity requirement, and the company has received a related Nasdaq deficiency notice. Accumulated deficit reached approximately $925.6 million as the company continues to invest in its preclinical oral obesity and metabolic disorders program, including lead compound ALN1003, which has shown encouraging diet-induced obesity mouse data.

The company discloses substantial doubt about its ability to continue as a going concern without raising additional capital and notes a material weakness in internal control over financial reporting, while also highlighting limited royalty income and continued cost reductions in general and administrative expenses.

Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.

Alaunos Therapeutics director Jaime Vieser reported an equity award. Vieser received a grant of 6,515 shares of Alaunos Therapeutics common stock at a price of $2.59 per share, increasing his directly held stake to 38,853 shares.

In addition to these direct holdings, the filing lists 13,503 shares held indirectly through Brushwood LLC, where Vieser is the manager, and 2,100 shares held indirectly for the benefit of his children.

Postma Robert W reported acquisition or exercise transactions in this Form 4 filing.

Alaunos Therapeutics director Robert W. Postma reported a stock-based compensation grant. On April 29, 2026, he received 6,274 shares of Alaunos Therapeutics common stock at $2.59 per share, issued in lieu of board fees. Following this grant, he directly holds 50,146 shares of common stock.

In addition to his direct holdings, Postma has indirect ownership interests, including 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal, and 24 shares held in his spouse’s IRA. The filing does not show any open-market purchases or sales, only this compensation-related award and updated ownership positions.

Alaunos Therapeutics, Inc. director Michael Allen Jerman received a grant of 6,032 shares of common stock on April 29, 2026, as a stock award issued in lieu of board fees. Following this compensation-related acquisition, he directly holds a total of 15,621 shares of Alaunos common stock.

Alaunos Therapeutics, Inc. filed an amendment to its annual report to add Part III information that had been omitted from the original Form 10-K. The amendment details the company’s board and governance structure, executive and director compensation, and security ownership of key stockholders and management.

The filing confirms a four‑member board, led by CEO and chair Holger Weis, and describes committee membership and independence under Nasdaq rules. It also outlines employment and consulting agreements, equity incentive plans, ownership concentrations among major holders, and audit fees paid to Cherry Bekaert LLP, without changing previously reported financial statements.

Alaunos Therapeutics, Inc. reported that Nasdaq notified the company on April 9, 2026 that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity to remain listed on the Nasdaq Capital Market. The company’s Form 10-K for the year ended December 31, 2025 reported stockholders’ equity of $2,153,000.

The company also does not currently meet Nasdaq’s alternative continued listing standards of a $35 million market value of listed securities or $500,000 in net income from continuing operations in the required periods. Alaunos has 45 calendar days from the date of the notice, until May 26, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to evidence compliance if the plan is accepted.

The company intends to submit a compliance plan and is evaluating potential actions to regain compliance. If the plan is not accepted, or if compliance is not regained within any extension, Alaunos would have the right to request a hearing before an independent Nasdaq panel, which would temporarily stay any suspension or delisting. Trading in the company’s securities is expected to continue following this disclosure if made within the required timeframe.

Alaunos Therapeutics, Inc. reports a strategic pivot to an early-stage, oral small‑molecule obesity and metabolic disorders program while warning of severe financial strain. For 2025, the company recorded a net loss of $4.2 million and an accumulated deficit of $924.6 million as of December 31, 2025.

Cash and cash equivalents were about $1.4 million, which management expects will fund operations only into the second quarter of 2026, raising substantial doubt about continuing as a going concern. Stockholders’ equity was $2.2 million, below Nasdaq’s $2.5 million equity requirement, creating renewed delisting risk.

The lead obesity candidate, ALN1003, has shown dose-dependent weight loss and metabolic improvements in diet‑induced obesity mouse models but remains in preclinical, non‑GLP studies with significant scientific, regulatory, financing, and execution risks. The company now has only one full-time employee and relies heavily on consultants, has identified a material weakness in internal control due to limited personnel, and highlights the possibility that failure to fund or advance the program could lead the board to consider dissolution and liquidation.